Evidence map›Paper›PMID 36159567›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2022

HBV Promotes the Proliferation of Liver Cancer Cells through the hsa_circ_0000847/miR-135a Pathway.

Jianjun Lin, Xiang Lian, Shihang Xue, Lian Ouyang, Lihui Zhou, Yuyang Lu, Longteng Xie

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Translational cancer research · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jianjun LinDepartment of Clinical Laboratory, Xiangshan First People's Hospital, Ningbo Fourth Hospital, Ningbo 315700, China.ORCID https://orcid.org/0000-0003-1107-3662
Xiang LianHepatology Department, Xiangshan First People's Hospital, Ningbo Fourth Hospital, Ningbo 315700, China.ORCID https://orcid.org/0000-0003-4967-6776
Shihang XueDepartment of General Surgery, Xiangshan First People's Hospital, Ningbo Fourth Hospital, Ningbo 315700, China.ORCID https://orcid.org/0000-0001-9973-3359
Lian OuyangDepartment of Orthopaedic Surgery, Xiangshan First People's Hospital, Ningbo Fourth Hospital, Ningbo 315700, China.ORCID https://orcid.org/0000-0002-6365-4007
Lihui ZhouDepartment of Orthopaedic Surgery, Xiangshan First People's Hospital, Ningbo Fourth Hospital, Ningbo 315700, China.ORCID https://orcid.org/0000-0001-9276-8196
Yuyang LuXiangshan County Center for Disease Control and Prevention, Ningbo 315700, China.ORCID https://orcid.org/0000-0003-3643-2166
Longteng XieHepatology Department, Xiangshan First People's Hospital, Ningbo Fourth Hospital, Ningbo 315700, China.ORCID https://orcid.org/0000-0003-1521-8697

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is currently one of the most common tumors, with a high morbidity and mortality rate. HCC induced by persistent hepatitis

Identifiers

PMID36159567
PMCPMC9499759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.